FOCUS on Mitochondria. This week is World Mitochondrial Disease Week and a great opportunity to focus on Focus Biomolecules’ Targeted Mitochondria Reagents. These unique reagents consist
FOCUS on Drug Approvals. On August 6 the FDA granted accelerated approval to Jazz Pharmaceuticals’ Dordaviprone (TIC10 or ONC-201) for patients with diffuse midline glioma harboring
FOCUS on Drug Approvals. On August 8 the FDA granted accelerated approval to Boehringer Ingelheim’s Zongertinib (BI 1810631) for adults with unresectable or metastatic non-squamous non-small
FOCUS on Clinical Trials. Today Celcuity announced the results of a Phase-3 clinical trial of Gedatolisib plus fulvestrant in patients with HR-positive, HER2-negative, PIK3CA wild-type locally
FOCUS on New Drug Targets: Epithelial-to-mesenchymal (EMT) transition is widely recognized as a cell-intrinsic process that augments the metastatic potential of cancer cells by enhancing motility
FOCUS on Stem Cell Rejuvenation. In the current issue of Cell Stem Cell, a group from Stanford reported that an endogenous eicosanoid, prostaglandin E2 (PGE2) reversed
BOGO
